{'52WeekChange': -0.18309855,
 'SandP52WeekChange': 0.0644362,
 'address1': '465 State Route 17',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.95,
 'askSize': 4000,
 'averageDailyVolume10Day': 2408312,
 'averageVolume': 2788884,
 'averageVolume10days': 2408312,
 'beta': 2.066106,
 'beta3Year': None,
 'bid': 2.9,
 'bidSize': 4000,
 'bookValue': 1.116,
 'category': None,
 'circulatingSupply': None,
 'city': 'Ramsey',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.98,
 'dayLow': 2.88,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.925,
 'enterpriseToRevenue': 6.866,
 'enterpriseValue': 247320256,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '201 478 5553',
 'fiftyDayAverage': 2.9544287,
 'fiftyTwoWeekHigh': 5.484,
 'fiftyTwoWeekLow': 1.45,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 67922677,
 'forwardEps': -0.25,
 'forwardPE': -11.6,
 'fromCurrency': None,
 'fullTimeEmployees': 313,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0735,
 'heldPercentInstitutions': 0.4791,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/admabiologics.com',
 'longBusinessSummary': 'ADMA Biologics, Inc., a biopharmaceutical and '
                        'specialty immunoglobulin company, develops, '
                        'manufactures, and markets specialty plasma-derived '
                        'biologics for the treatment of immune deficiencies '
                        'and infectious diseases in the United States. It '
                        'offers BIVIGAM, an intravenous immune globulin '
                        'product indicated for the treatment of primary '
                        'humoral immunodeficiency (PI); ASCENIV, an IVIG '
                        'product for the treatment of PI; and Nabi-HB, which '
                        'is indicated for the treatment of acute exposure to '
                        'blood containing Hepatitis B surface antigen and '
                        'other listed exposures to Hepatitis B. It also '
                        'develops a pipeline of plasma-derived therapeutics, '
                        'including products related to the methods of '
                        'treatment and prevention of S. pneumonia infection '
                        'for an immunoglobulin. In addition, the company '
                        'operates source plasma collection facilities. The '
                        'company distributes its products through independent '
                        'distributors, sales agents, specialty pharmacies, and '
                        'other alternate site providers. ADMA Biologics, Inc. '
                        'was founded in 2004 and is headquartered in Ramsey, '
                        'New Jersey.',
 'longName': 'ADMA Biologics, Inc.',
 'market': 'us_market',
 'marketCap': 250401360,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_51119246',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -54456592,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.93,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '201 478 5552',
 'previousClose': 2.96,
 'priceHint': 4,
 'priceToBook': 2.5985663,
 'priceToSalesTrailing12Months': 6.951685,
 'profitMargins': -1.51183,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.98,
 'regularMarketDayLow': 2.88,
 'regularMarketOpen': 2.93,
 'regularMarketPreviousClose': 2.96,
 'regularMarketPrice': 2.93,
 'regularMarketVolume': 954693,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 86345296,
 'sharesPercentSharesOut': 0.1107,
 'sharesShort': 9557443,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 9959896,
 'shortName': 'ADMA Biologics Inc',
 'shortPercentOfFloat': 0.1521,
 'shortRatio': 3.45,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'ADMA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.89,
 'twoHundredDayAverage': 3.1230936,
 'volume': 954693,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.admabiologics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '07446'}